Fidasimtamab

N/A

Report date: 2025/03/13 15:10:58

Base Information

Drug NameFidasimtamab
Drug Alias Nameanti-PD-1/anti-Her2 bispecific antibodyPD-1/Her2 BsABIBI-315BH-2950
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionProgrammed cell death protein 1 blockersReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsProgrammed cell death protein 1Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHanmi Pharmaceutical Co LtdInnovent Biologics(Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHanmi Pharmaceutical Co LtdInnovent Biologics(Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A